Related Experiment Video
Updated: Jul 19, 2026
09:40
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms
André Oberthuer1, Frank Berthold, Patrick Warnat
1Children's Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Kerpener Strasse 62, D-50924 Cologne, Germany. andre.oberthuer@uk-koeln.de
Summary
A new gene expression classifier accurately predicts neuroblastoma patient outcomes. This tool improves risk stratification compared to current methods, potentially enhancing treatment strategies for neuroblastoma (NB).
Area of Science:
- Oncology
- Genomics
- Biostatistics
Background:
- Neuroblastoma is a pediatric cancer with variable clinical courses.
- Accurate prediction of disease progression is crucial for effective treatment stratification.
- Current risk stratification systems require refinement for improved patient management.
Purpose of the Study:
- To develop a gene expression-based classifier for neuroblastoma patients.
- To reliably predict the clinical course and outcomes of neuroblastoma.
- To compare the classifier's performance against existing risk stratification systems.
Main Methods:
- Analyzed 251 neuroblastoma specimens using a custom oligonucleotide microarray with 10,163 probes.
- Applied Prediction Analysis for Microarrays (PAM) to identify a 144-gene predictor.
- Validated the classifier in an independent cohort (n=174) and compared it with international trial risk stratification.
Main Results:
- The PAM classifier achieved 99% cross-validated accuracy in the initial patient set.
- In the independent set, the classifier significantly separated patients into favorable and unfavorable outcome groups (P < .0001).
- The gene expression predictor outperformed current risk stratification systems in multivariate analysis (P < .001; HR=4.756).
Conclusions:
- Gene expression-based classification offers a powerful tool for predicting neuroblastoma patient outcomes.
- This approach can significantly refine risk estimation beyond current clinical trial systems.
- Integration of this classifier may improve the management and treatment strategies for neuroblastoma.